Compare Stocks → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison CVE:MPHNYSEARCA:QPTNASDAQ:RZLTNASDAQ:SBTX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMPHMedicureC$1.02-6.4%C$1.14C$0.99▼C$1.80C$10.46M1.014,477 shs10,000 shsQPTAdvisorShares Q Portfolio Blended Allocation ETF$19.10+0.1%$19.10$18.63▼$27.54$1.91MN/A1,912 shs19,400 shsRZLTRezolute$2.60-10.0%$2.19$0.72▼$3.69$104.33M1.29314,242 shs454,240 shsSBTXSilverback Therapeutics$8.09-2.1%$8.82$2.80▼$8.97$291.71M0.6337,931 shs534,599 shsBeginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMPHMedicure-6.42%-0.97%-15.00%-12.07%-22.14%QPTAdvisorShares Q Portfolio Blended Allocation ETF0.00%0.00%0.00%0.00%0.00%RZLTRezolute-10.03%-21.21%+22.64%+136.36%+30.00%SBTXSilverback Therapeutics-2.06%-10.71%-19.10%+24.08%+24.46%“Retirement Secret” Showed 995% Gain Last Time We Shared It (Ad)Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.Find out why right here (and see what you can do to get in too with just a few dollars).MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMPHMedicureN/AN/AN/AN/AN/AN/AN/AN/AQPTAdvisorShares Q Portfolio Blended Allocation ETFN/AN/AN/AN/AN/AN/AN/AN/ARZLTRezolute3.7369 of 5 stars3.54.00.00.03.74.20.6SBTXSilverback TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMPHMedicureN/AN/AN/AN/AQPTAdvisorShares Q Portfolio Blended Allocation ETF0.00N/AN/AN/ARZLTRezolute3.00Buy$8.80238.46% UpsideSBTXSilverback TherapeuticsN/AN/AN/AN/ACurrent Analyst RatingsLatest SBTX, MPH, RZLT, and QPT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/18/2024RZLTRezoluteJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$7.004/18/2024RZLTRezoluteJonestradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.004/9/2024RZLTRezoluteMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$8.003/7/2024RZLTRezoluteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.002/14/2024RZLTRezoluteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMPHMedicureC$22.94M0.46C$0.41 per share2.49C$2.10 per share0.49QPTAdvisorShares Q Portfolio Blended Allocation ETFN/AN/AN/AN/AN/AN/ARZLTRezoluteN/AN/AN/AN/A$3.15 per shareN/ASBTXSilverback TherapeuticsN/AN/AN/AN/A$7.41 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMPHMedicureC$1.08MC$0.0911.33∞N/A4.71%5.04%2.49%5/24/2024 (Estimated)QPTAdvisorShares Q Portfolio Blended Allocation ETFN/AN/A0.00∞N/AN/AN/AN/AN/ARZLTRezolute-$51.79M-$1.10N/AN/AN/AN/A-51.81%-48.05%5/9/2024 (Estimated)SBTXSilverback Therapeutics-$89.48M-$2.42N/A∞N/AN/A-29.62%-28.20%N/ALatest SBTX, MPH, RZLT, and QPT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/8/2024Q4 2023MPHMedicureN/A-C$0.14-C$0.14-C$0.14N/AC$5.07 million2/13/2024Q2 2024RZLTRezolute-$0.27-$0.27N/A-$0.27N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMPHMedicureN/AN/AN/AN/AN/AQPTAdvisorShares Q Portfolio Blended Allocation ETF$0.080.42%N/AN/AN/ARZLTRezoluteN/AN/AN/AN/AN/ASBTXSilverback TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMPHMedicure2.862.281.29QPTAdvisorShares Q Portfolio Blended Allocation ETFN/AN/AN/ARZLTRezoluteN/A12.0012.00SBTXSilverback TherapeuticsN/A67.8767.87OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMPHMedicure23.10%QPTAdvisorShares Q Portfolio Blended Allocation ETFN/ARZLTRezolute82.97%SBTXSilverback Therapeutics74.89%Insider OwnershipCompanyInsider OwnershipMPHMedicure26.99%QPTAdvisorShares Q Portfolio Blended Allocation ETFN/ARZLTRezolute18.20%SBTXSilverback Therapeutics34.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableMPHMedicureN/A10.25 millionN/ANot OptionableQPTAdvisorShares Q Portfolio Blended Allocation ETFN/A100,000N/ANot OptionableRZLTRezolute5740.13 million32.83 millionNot OptionableSBTXSilverback Therapeutics8336.06 million23.65 millionNot OptionableSBTX, MPH, RZLT, and QPT HeadlinesSourceHeadlineSilverback Therapeutics (NASDAQ:SBTX) Trading Down 2.8%americanbankingnews.com - April 25 at 1:48 AMSilverback Therapeutics (NASDAQ:SBTX) Trading Down 2%marketbeat.com - April 3 at 2:15 AMARS Pharmaceuticals Inc (SPRY)uk.investing.com - May 11 at 1:32 PMWild Isleswwf.org.uk - March 12 at 9:31 AMA look back at RNA Therapeutics – day onepharmaphorum.com - February 24 at 12:35 AMSPRY ARS Pharmaceuticals, Inc.seekingalpha.com - January 24 at 8:04 PMARS Pharma CEO Richard Lowenthal Holds 8% Silverback Stake After Merger247wallst.com - November 22 at 6:29 AMDr. Sarina Tanimoto Discloses Position in SBTX / Silverback Therapeuticsnasdaq.com - November 18 at 8:19 PMARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxisfinance.yahoo.com - November 10 at 6:41 PMARS Pharmaceuticals Closes Merger with Silverback Therapeuticsfinance.yahoo.com - November 8 at 5:59 PMSilverback : FDA Accepts ARS Pharm's NDA For Neffy For Treatment Of Allergic Reactionsmarkets.businessinsider.com - October 28 at 8:15 AMFDA accepts ARS Pharma’s NDA for Neffythepharmaletter.com - October 24 at 10:29 AMSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HIL, SBTX, COWN, AERIkentuckytoday.com - October 23 at 7:22 PMSilverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including Anaphylaxisfinance.yahoo.com - October 21 at 7:59 AMIs Silverback Therapeutics Inc (SBTX) Stock a Good Investment?aaii.com - October 19 at 11:52 AMSHAREHOLDER ALERT: The M&A Class Action Firm is Investigating the Merger – RFP, SBTX, AAWW, COWNbakersfield.com - October 12 at 11:07 PMINVESTIGATION ALERT: Halper Sadeh LLC Investigates CVET, SBTX, IRBTmarkets.businessinsider.com - September 17 at 5:10 AMSBTX Silverback Therapeutics, Inc.seekingalpha.com - September 15 at 10:58 PMSHAREHOLDER NOTICE: Halper Sadeh LLP Investigates FTAI, SBTX, CVET, GBTmarkets.businessinsider.com - September 6 at 11:53 AMSHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates HNGR, SBTX, IEA, ZYmarkets.businessinsider.com - August 23 at 6:32 PMSHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates VIVO, HNGR, SBTXapnews.com - August 17 at 12:02 PMSHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates IEA, BBQ, SBTXapnews.com - August 11 at 1:33 AMSHAREHOLDER ALERT: Weiss Law Reminds SBTX, LJPC, CNVY, and DRE Shareholders About Its Ongoing Investigationsmorningstar.com - July 30 at 7:00 AMINVESTIGATION ALERT: Halper Sadeh LLP Investigates HNGR, SBTX, IEA, ZYapnews.com - July 28 at 2:21 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsMedicureCVE:MPHMedicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.AdvisorShares Q Portfolio Blended Allocation ETFNYSEARCA:QPTRezoluteNASDAQ:RZLTRezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.Silverback TherapeuticsNASDAQ:SBTXSilverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.